9000 Virginia Manor Rd. Suite 200
35 articles with NextCure, Inc.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2019 financial results and provided a business update.
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced a proposed public offering of 3,200,000 shares of its common stock.
NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
NextCure, Inc. announced that the company will host and webcast an event with its Chief Medical Officer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer on Saturday, November 9, 2019 at 6:30 p.m. Eastern Time at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
Although 2018 marked a record year for biopharma initial public offerings (IPO), 2019 has had a number of IPOs so far as well. Here’s a look at four recent IPO filings—and $86 million appears to be the magic number.
New Haven, Conn.-based NextCure and the Yale University Office of Corporate Research (OCR) announced the publication of a study describing Siglec-15 (S15), a new target for immunotherapy. The article was published in the journal Nature Medicine.
NextCure Announces Formation of Scientific Advisory Board to Guide Development of its Portfolio of Immunomedicines
NextCure, Inc., announced the appointment of renowned researchers and thought leaders with expertise in immunology, oncology and drug development to a newly formed scientific advisory board.
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
-- Proceeds Will Advance Growing Portfolio of Novel Immunomedicine Drug Candidates --
NextCure to Present Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
NextCure, Inc. today announced that preclinical data supporting the development of its lead drug candidate, NC318, will be presented in a poster session at the Society for Immunotherapy of Cancer 33rd Annual Meeting being held November 7th – 11th 2018 in Washington, D.C.
Lilly is paying NextCure $25 million upfront. NextCure will be eligible for various development and commercial milestone payments, as well as royalties on any commercial products. In addition, Lilly invested $15 million in NextCure equity.
NextCure Appoints Kevin N. Heller, M.D., as Chief Medical Officer and Steve Cobourn, CPA, as Chief Financial Officer
Both are accomplished executives with proven track records in building biopharmaceutical companies.